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Background: Distinct subpopulations of neoplastic cells within tumors, including hepatocellular carcinoma (HCC),
display pronounced ability to initiate new tumors and induce metastasis. Recent evidence suggests that signals from
transforming growth factor beta (TGF-β) may increase the survival of these so called tumor initiating cells leading to
poor HCC prognosis. However, how TGF-β establishes and modifies the key features of these cell subpopulations is not
fully understood.
Results: In the present report we describe the differential DNA methylome of CD133-negative and CD133-expressing liver
cancer cells. Next, we show that TGF-β is able to increase the proportion of CD133+ cells in liver cancer cell lines in a
way that is stable and persistent across cell division. This process is associated with stable genome-wide changes in DNA
methylation that persist through cell division. Differential methylation in response to TGF-β is under-represented at
promoter CpG islands and enriched at gene bodies, including a locus in the body of the de novo DNA methyl-transferase
DNMT3B gene. Moreover, phenotypic changes induced by TGF-β, including the induction of CD133, are impaired by
siRNA silencing of de novo DNA methyl-transferases.
Conclusions: Our study reveals a self-perpetuating crosstalk between TGF-β signaling and the DNA methylation
machinery, which can be relevant in the establishment of cellular phenotypes. This is the first indication of the ability
of TGF-β to induce genome-wide changes in DNA methylation, resulting in a stable change in the proportion of liver
cancer cell subpopulations.
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Hepatocellular carcinoma (HCC) is the major form of
primary liver cancer [1], and typically originates in a
background of chronic inflammation caused by various
factors, such as alcohol consumption, or viral infection
(hepatitis B and hepatitis C) [2]. Inflammation is an
essential part of the wound-healing response to those
risk factors. However, chronic inflammation favors the
accumulation of mutations and epigenetic aberrations in* Correspondence: vargash@iarc.fr; herceg@iarc.fr
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unless otherwise stated.hepatocytes, thereby promoting malignant transfor-
mation [3,4]. This process is mediated by chemokines,
cytokines, and growth factors secreted by the stromal
components of the liver microenvironment [4]. Among
those secreted factors, the transforming growth factor
beta (TGF-β) has been shown to have a key role that is
cell-type dependent and variable during the hepato-
carcinogenesis process [5]. In established HCC, TGF-β
overexpression is associated with poor prognosis [6-8].
However, characterization of the tumor cells targeted by
TGF-β in HCC is still lacking.
As has been shown for other human malignancies, a
subpopulation of cancer cells in HCC is known toLtd. This is an Open Access article distributed under the terms of the Creative
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called tumor-initiating cells (TICs), are defined by their
self-renewal and differentiation capacity, and have been
isolated based on their expression of several cell markers
(EpCAM, CD133, CD90, CD44, CD24, CD13, and OV6) [9].
Of these, the surface marker CD133/Prominin1[PROM1]
has been one of the most consistently reported. CD133
is a transmembrane protein whose function is only par-
tially known [12,13], but that may represent a marker of
a distinct cell subpopulation with defined characte-
ristics. The functional characterization of these cells will
increase our understanding of the mechanisms involved
in promoting and sustaining liver cancer progression.
Several recent reports suggest a link between TGF-β sig-
naling and liver TICs. Firstly, signaling pathways identified
in liver cancer, including TGF-β, are active in isolated liver
TICs [14]. Secondly, TGF-β-induced epithelial-mesenchy-
mal transition generates self-renewing cells, a process also
implicated in a higher risk of tumor metastasis, as inva-
siveness and self-renewal are frequently shared features of
stem cells, TICs and metastatic cells [15,16]. Finally, a
recent study showed that TGF-β is able to induce the
expression of CD133 in liver cancer cell lines together
with an increased tumor initiating ability in mice [17].
Together, these studies point towards a specific role for
TGF-β in inducing a TIC program in HCC.
DNA methylation is able to stably modify the cell
phenotype through cellular division [18]. Because of the
relative stability of DNA methylation marks, DNA me-
thylation is a strong candidate mechanism to translate
the presence of TGF-β in the cellular microenvironment
into persistent changes in phenotype. However, there is
still limited evidence of a link between exposure to com-
ponents of the tumor microenvironment and the in-
duction of stable changes in DNA methylation in target
cells.
In this study, we first defined the DNA methylome
profile of CD133-expressing liver cancer cells. We then
tested the potential association between DNA methyla-
tion and the induction of liver CD133+ cells by TGF-β.
We show that TGF-β function in this context is intim-
ately linked to a change in DNA methylation profiles,
and that this may represent a key process in the estab-
lishment of chronic exposure imprints in liver cancer
cells.
Results
CD133- and CD133+ liver cancer cells differentially
express DNA methylation genes
CD133 is an established marker of TICs in different
types of human malignancies, including HCC [12]. To
test the notion that this marker distinguishes a cell sub-
population with a distinct DNA methylation program,
we characterized two non-related liver cancer cell lines.In a first step, we estimated the frequency of CD133
expressing cells in Huh7 and HepG2 liver cancer cells
using fluorescence-activated cell sorting (FACS) against
all common CD133 isoforms [12]. The expression of
CD133 was evident in both cell lines, with a mean of
5% (SD = 2%) in HepG2, and 25% (SD = 13%) in Huh7
(Figure 1a). Expression of the surface protein positively
correlated with CD133 expression at the mRNA level
(data not shown). This low to moderate percentage
of cells expressing CD133 contrasts with the extreme
values of expression that we observed for other mole-
cules such as CD90, CD44 or EpCAM (Additional file 1:
Figure S1a). Importantly, expression of CD133 by FACS
has been tested at different time points throughout se-
veral years, in multiple conditions of cell passages and
confluence.The relatively low variability on CD133 ex-
pression across time and conditions suggests a dynamic
balance between CD133-expressing and non-expressing
fractions in both cell lines.
To serve as a basis for exploring a potentially different
methylation program in CD133+ liver cancer cells, we
studied the expression of genes coding for relevant players
of the DNA methylation machinery. This included genes
involved in maintenance of DNA methylation (DNMT1),
de novo DNA methylation (DNMT3A and DNMT3B)
and DNA demethylation (TET1 and TET2). Notably,
DNMT3A was consistently and significantly overexpressed
in both Huh7 and HepG2 cells progressively enriched for
CD133 (Figure 1b). In addition, DNMT3B was overex-
pressed in HepG2 CD133-enriched cells, while TET2 dis-
played opposite differential expression in CD133-enriched
Huh7 and HepG2 cells (Figure 1b). As noted above, the
stable balance between the two cell fractions suggests no
substantial difference in cell cycle rate between them.
Therefore, significant differences in expression, although
modest in magnitude, are compatible with true functional
differences between the two subpopulations.
Together, these data suggests that CD133 positive and
negative fractions grow in a constant proportion within
liver cancer cell lines. They differentially express de
novo DNA methylation genes (DNMT3A in both cell
lines, and DNMT3B in HepG2) and a subset of genes in-
volved in stemness (Additional file 1: Figure S1b). Func-
tionally, expression of this marker has been associated
with an increased tumor-initiating ability and ability
to grow in non-attachment conditions, a well known
surrogate measure of TIC-like activity. We found that
MACS-sorted CD133+ Huh7cells were able to form
spheres under non-attachment conditions, in con-
trast to their CD133- counterpart (Additional file 1:
Figure S1c). This was not the case with HepG2 cells,
where no sphere formation was observed, possibly due
to the lower enrichment of CD133+ cells that was
attained using MACS.
Figure 1 CD133- and CD133+ liver cancer cells differentially
express genes involved in DNA methylation establishment and
maintenance. a. Liver cancer cell lines (Huh7, and HepG2) were
assessed for surface expression of CD133 by flow cytometry. The left
panel shows a representative histogram for each of the cell lines (black
histogram), with background (secondary antibody) represented by the
empty histogram (logarithmic scale). The average expression +/- SD
from three assays is shown in the right panel. b. The same cell
lines were sorted using MACS (as described in Methods) and
RNA was extracted to measure the expression levels of the
genes involved in DNA methylation or demethylation. Expression
was normalized to the housekeeping gene GAPDH. (*) indicates
P value < 0.05.
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CD133+ liver cancer cells
The above results support the hypothesis of a phenotypic
and functional distinction between CD133+ and CD133-
cell fractions. CD133+ cells display a higher expression of
de novo DNMTs, and this may be reflected in a differen-
tial configuration of their DNA methylome. To study this
possibility, we performed a genome-wide DNA methy-
lome analysis in FACS-sorted CD133- and CD133+ frac-
tions from Huh7 and HepG2 cells (Figure 2a). DNA
isolated from these fractions was interrogated with the
Illumina Infinium HM450 bead array, which covers differ-
ent genomic features of interest in addition to most hu-
man bona fide CpG islands [19]. We first performed
unsupervised analyses and found that parental cell line
was the main factor defining DNA methylation vari-
ation. Therefore, our main analysis compared CD133-
to CD133+ fractions accounting for cell of origin
(Methods). The class comparison analysis resulted in 823
differentially methylated probes [corresponding to 472 an-
notated genes] at significant p value (p < 0.001), although
relatively high FDRs (FDR = 0.58), probably due to sample
and cell line variations. Therefore, for downstream data
mining, we increased the stringency of the analyses by fur-
ther filtering the significant list to keep only those CpG sites
where the average differential methylation was at least 5%
between the two groups in both cell lines. The resulting
608 differentially methylated probes correspond to 394
RefSeq genes, and represent those CpG sites significantly
hypo or hypermethylated in CD133+ cells in both cell lines,
relative to their negative counterpart (Additional file 2:
Table S1). Most of these probes (n = 510, 84%) were
hypomethylated in CD133+ cells, while 98 (16%) were
hypermethylated (Figure 2b). An important proportion
of differentially methylated loci (45%) were not related
to CpG islands (CGI) or their neighboring shelves and
shores (“open sea” probes in Figure 2c). For those
probes matching annotated genes, we found a signifi-
cant overrepresentation of differentially methylated loci
Figure 2 Differential DNA methylome between CD133- and
CD133+ liver cancer cells. a. Huh7 and HepG2 cells were FACS
sorted using CD133 antibody. Gates used to select negative and
positive fractions are depicted in the upper panels. Duplicates of
each fraction were used for HM450 bead array DNA methylation
analyses. b. Median methylation (and distribution) for all differentially
methylated loci (P < 0.001) distinguishing CD133- versus CD133+ in
both cell lines. c. Significant loci were distributed according to CpG
island relationship as Island, north shore, south shore, north shelf, south
shelf, and “Open sea”, and are represented in the upper pie chart. The
lower pie chart represents the distribution of significant loci in relation
to annotated genes (within 200 or 1500 bp from the TSS, first exon,
3′ or 5′ UTRs, and gene body). d. AVG_Beta values obtained from the
bead array assay were plotted for one significant CpG site within the
CD133(PROM1) promoter. The difference in methylation between
CD133- and CD133+ cells (delta_Beta) is indicated for each cell line.
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to gene position and CpG island status was similar for
hypomethylated sites, while hypermethylated sites were
even more enriched in both, open sea (64%) and gene
body (57%) probes (data not shown). Supporting the
quality of the dataset was the finding of one CpG site
within the CD133 (Prominin1 [PROM1]) locus among
this list of differentially methylated sites. This CpG site
was hypomethylated in CD133+ subpopulations from
both cell lines, by 4.4% and 8% in Huh7 and HepG2
cells, respectively (Figure 2d).
After having identified differentially methylated CpGs
and the genes associated with these sites, we next aimed
to identify the pathways that are specifically altered in
CD133+ cells. To this end, we performed pathway analysis
considering methylome profiles of both cell lines together
or independently. Notably, in both cases there was enrich-
ment in pathways previously associated with tumor ini-
tiating cell activity, such as Jak-STAT, Notch, Wnt and
Akt (Additional file 3: Table S2). Other pathways included
actin cytoskeleton, focal adhesion, and cell adhesion. In
addition, there was a significant overrepresentation of
inflammatory pathways, such as NFkB, p38, TNF, and
TGF-β signaling pathways.
In summary, our data shows that CD133+ and CD133-
liver cancer cells display a different DNA methylome. In
spite of the cell line specific profiles, the data suggests a
common CD133+ methylome signature, which includes
the PROM1 gene itself. In addition, the methylome of
CD133+ cells is characterized by a global reduction in
DNA methylation relative to their CD133- counterpart,
with an overrepresentation of non-CGI CpG sites. For
those differentially methylated sites related to annotated
genes (and mainly found in the gene bodies), there was an
association with TIC- and inflammation-related pathways.
These findings suggest that specific DNA methylation
profiles are associated to the phenotype and functionality
of these cell subpopulations.
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fashion
It has been reported that TGF-β exposure increases the
percentage of CD133+ cells in the Huh7 cell line [17],
although the underlying mechanism remains largely un-
known. We thus aimed to investigate whether this ob-
servation is consistent in two independent cell lines and
compatible with an epigenetic mechanism (i.e. persistent
through cell division). Importantly, both Huh7 and
HepG2 cells, express the receptor for TGF-β (TGFBRII)
at similar levels, and respond to TGF-β by phosphory-
lating the receptor-dependent SMAD3 (Additional file 4:
Figure S2a and S2b). In addition to TGF-β, we per-
formed a set of parallel experiments with the pro-inflam-
matory cytokine interleukin 6 (IL-6), which has also
been associated with HCC risk [20]. To this end, we
selected commonly used cytokine concentrations that
induced morphological changes after 4 days of treatment
in both cell lines (in the case of TGF-β), but did not
have any effect on cell viability (Additional file 4: Figure
S2c and S2d). As expected, TGF-β exposure during 4
days induced a two-fold increase in the percentage of
CD133+ cells in Huh7 and HepG2 cells (Figure 3a).
Interestingly, IL-6 treatment also induced an increase in
CD133 positivity in both cell lines, although the increase
was comparatively mild (approximately 50% increase)
(Figure 3a). Next, we analyzed the persistence of the
effect in CD133 expression induced by both cytokines.
To this end, we treated both cell lines as in the previous
experiment. After 4 days, cell culture medium was
replaced by standard medium, and cells were left in
culture for additional 4 days. Cells were collected and
screened for CD133 expression using FACS. Notably,
only cells treated with TGF-β showed a persistent in-
crease in the percentage of CD133+ cells, of similar
magnitude to the increase observed at day 4 (Figure 3a).
Importantly, only TGF-β exposure was able to induce a
significant increase in the expression of CD133 at the
transcriptional level in both cell lines (8 and 6 fold in-
crease for Huh7 and HepG2, respectively) (Additional
file 5: Figure S3b).
TGF-β is a member of a large family of pleiotropic
cytokines that signal through a receptor complex com-
prising a diversity of type I and type II serine/threonine
kinases. The recombinant TGF-β1 used in our assays is
expected to bind the activin receptor-like kinase (ALK)5
(the TGF-beta type I receptor) [21]. To rule out un-
specific effects of this treatment, we used the small mo-
lecule inhibitor SB-431542, which targets ALK5 and
ALK5-related type I receptors, with no effect on other
family members that, for example, recognize bone mor-
phogenetic proteins (BMPs) [22]. By using this specific
inhibitor of TGF-β pathway, we were able to abrogate
the effect of TGF-β in inducing CD133 expression(as well as the morphological changes) in both cell lines
(Figure 3b and Additional file 4: Figure S2e). Therefore,
the ability to induce CD133+ cells is specific and fully
dependent on TGF-β type I receptor signaling in both,
Huh7 and HepG2 cells (Figure 3b).
Together, these findings suggest that TGF-β is able to
specifically and stably induce CD133 expression (in con-
trast to the milder and transient effect of IL-6), an obser-
vation consistent with epigenetically-induced phenotype
persistence.
De novo induction of CD133 by TGF-β is associated to an
increased expression of DNMT3 genes
The increase in CD133 positivity induced by TGF-β can
be explained by a switch in the expression of CD133, or
an increased rate of growth specifically in the smaller
CD133+ fraction of cells. To distinguish between these
two possibilities, we repeated the previous experiment in
cells negative for CD133 expression, selected by depletion
of CD133+ cells using MACS (Methods). In both cell
lines, TGF-β was able to significantly induce a population
of CD133+ cells, evident after 4 days of treatment
(Figure 4a). Also in this case, we replaced the medium
after 4 days, and let the cells grow in the absence of cyto-
kines for additional 4 days. After these additional 4 days,
the increase in CD133 positive fraction was higher, relative
to the one observed at day 4, for both cell lines (Figure 4a,
and Figure 3a for comparison). Importantly, although
there was a spontaneous induction of a CD133+ fraction
in Huh7 cells (from 0 to 20% after 4 days), this percentage
did not significantly change at day 8, and is similar to what
is found in untreated Huh7 cells in basal conditions. As
discussed above, this suggests a dynamic balance between
the CD133 negative and positive fractions in this cell line.
The surface expression of CD133 remained close to zero
in HepG2 control cells. This finding suggests that TGF-β
is able to induce the expression of CD133 surface protein,
and not an increased proliferation of CD133+ cells. This is
also supported by the expected lower rate of proliferation
of cells treated with TGF-β (Additional file 5: Figure S3a).
Similar to our previous experiment, under these condi-
tions IL6 only showed a transient effect (Figure 4a).
After having shown that TGF-β may be able to induce a
de novo fraction of CD133+ cells, we asked whether this
effect correlated with a differential expression of DNA
methylation players, as we have shown that CD133+ cells
overexpress DNMT3 genes in basal culture conditions
(Figure 1b). DNMTs and TET2 displayed a significant in-
crease in mRNA expression in at least one of the two cell
lines, while TET1 was underexpressed after 4 days of re-
lease from TGF-β exposure (Figure 4b). As shown for the
basal CD133-expressing cells (i.e. those isolated from un-
treated HCC cell lines), the most consistent finding was
the statistically significant overexpression of DNMT3A in
Figure 3 TGF-β, but not IL-6, induces CD133 expression in a
stable fashion. a. Experimental design is indicated in the upper
panel. Huh7 and HepG2 cells were grown in control culture
conditions (depicted in gray text and lines), or exposed to 10 ng/ml
IL-6 (red) or 10 ng/ml TGF-β (blue) for 4 days. Cells plated in parallel,
had their medium replaced by control culture medium and were left
in culture for additional 4 days. FACS expression of surface CD133
protein is shown for day 0, day 4, and day 8 (4 days treatment + 4
days post-release) for all conditions, in logarithmic scale. Histograms
are shown for one representative replicate in the middle panel.
Mean +/- SD is shown for three biological replicates in the lower
panel barplots. b. TGF-β type I receptor antagonist SB 431542 was
used at 2uM, alone or in combination with 10 ng/ml of TGF-β, and
DMSO used as control. CD133 expression was studied by FACS after
4 consecutive days of exposure to each experimental condition.
(*) indicates P value < 0.05 relative to all other conditions, for both
cell lines. Representative phase contrast images are shown in the
lower panels.
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the conditions of study was IL-6 exposure able to induce
statistically significant changes at the mRNA expression
level of genes related to DNA methylation/demethylation
(Figure 4b).
Combined, these data shows the ability of TGF-β (in
contrast to IL-6) to induce a stable de novo fraction of
CD133-expressing cells in two independent liver cancer
cell lines. This induction correlates with a functional
characteristic of basal CD133+ cells, which is the in-
creased ability to grow under non-attachment cell cul-
ture conditions (Figure 4c). Moreover, the persistence of
CD133 induction by TGF-β (4 days after release from
TGF-β treatment, and at least two cell divisions apart)
suggests an epigenetic process is taking place, in contrast
to the transient induction of CD133 by IL-6.
Cell subpopulation switch induced by TGF-β correlates
with a differential DNA methylome
Having shown that CD133+ cells display a unique DNA
methylome, and that TGF-β is able to induce a de novo
CD133+ fraction of cells, we decided to study the DNA
methylome induced by TGF-β exposure. To this end, we
used HM450 bead arrays to interrogate DNA methylation
changes induced by 4 days of TGF-β exposure in both,
Huh7 and HepG2 cells (Figure 5a). In addition, to define
the epigenetic persistence of TGF-β effects, we included
the DNA from cells released 4 days into normal cell cul-
ture medium after the TGF-β treatment. As described
above for the DNA methylation profile of CD133-expres-
sing cells, the methylome of Huh7 and HepG2 cells are
clearly distinguishable, independently of the experimental
conditions. However, in addition to cell type-specific
changes we were able to observe genome-wide changes
induced by TGF-β in a cell type-independent fashion. To
define a TGF-β-induced DNA methylation signature, we
focused on those loci that were significantly hypo or
Figure 4 (See legend on next page.)
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Figure 4 de novo CD133 induction by TGF-β correlates with overexpression of DNMT3 genes. a. the experiment in Figure 3A was repeated
after MACS-sorting to enrich in CD133 negative cells, as depicted in the upper panel. Levels of CD133 expression were close to 0%, as shown in the
upper histograms for both, Huh7 and HepG2 cells. Mean from three replicates is shown in the lower panels. (*) indicates P value < 0.05 relative to
control conditions. b. sphere formation assays were performed in non-attachment plates, after exposure to TGF-β during 4 days. Spheres were counted
after 6 days of growth in hepatosphere medium w/o TGF-β. c. Huh7 (left panels) and HepG2 (right panel) cells were treated as in (a), RNA was
extracted and qRT-PCR was performed for genes involved in DNA methylation or demethylation. Expression was normalized to housekeeping gene
GAPDH. (*) indicates P value < 0.05 relative to non-treated cells at the corresponding time point.
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interested in those changes that were persistent through
cell division and stable in the absence of TGF-β. There-
fore, we selected significant loci (FDR < 0.05) that were
differentially methylated at both, 4 days of treatment and
4 additional days after release. Finally, we selected those
CpG sites that reached an average difference of at least
10% between control and TGF-β conditions (Figure 5b).
555 differentially methylated positions (DMPs) fulfill all
criteria, with 115 hypomethylated after TGF-β exposure
(21%) and a great majority hypermethylated (n = 440,
82%) (Additional file 6: Table S3), including multiple sites
on intergenic regions. Hypermethylated DMPs included
loci in TRRAP, COL1A1, DNAH17, ARID1B, ONECUT2,
and DNMT3B. Hypomethylated DMPs included loci
in TGFB2, BMP1, IRAK2, and FOXK2. Interestingly,
there was an enrichment of DMPs on enhancer regions
(Figure 5c). In addition, we found a significantly lower GC
content in DMPs when compared to a random selection
of probes or to the overall GC content of HM450 probes
(Figure 5d). To study the genomic context in more detail
we analyzed the overlap of DMPs with genomic features,
as previously described [23]. These annotations consider
the relationship with CpG islands (CGI) (i.e. islands,
shores, shelves, or open sea) and the location with respect
to the gene (i.e. distal and proximal promoter, gene body,
distal, and intergenic sequences). An important pro-
portion of probes in HM450 bead arrays target proximal
promoter CGIs and shores, and non-CGI gene bodies
(HM450 in Figure 5e). A similar distribution is observed
when overlapping a randomly generated list of sites (of
the same size of the DMP list, n = 555) with the genomic
features. However, there is a striking under-representation
of promoter CGIs and shores in the DMP list (Figure 5e).
Instead, a great majority of DMPs are found within the
gene bodies in non-CGI regions, in agreement with our
previous observation of low GC content (Figure 5d).
Next, we searched for differentially methylated regions
(DMRs) in response to TGF-β, and common to both cell
lines. We used as criteria for DMR the presence of at
least two neighboring DMPs within a minimum gap of
100bp at a significant FDR < 0.05. Using these criteria we
obtained 18 DMRs, oscillating from 2 to 6 DMPs on
each (Table 1). Interestingly, one of these DMRs is com-
prised of 3 CpG sites corresponding to the body of theDNMT3B gene. Indeed, the majority of DMRs (16 out of
18) were found outside of gene promoters. DMPs in
DNMT3B and TRRAP were validated using an indepen-
dent quantitative method, bisulfite DNA pyrosequencing
(Figure 5f). Both assays confirmed hypermethylation in
response to 4 days of TGF-β and 4 days after release, in
the two cell lines. In contrast, no differential methylation
was observed in pyrosequencing assays performed on
DNMT3A and TET2 in response to TGF-β, although in-
creased methylation at the DNMT3A locus was observed
after IL-6 exposure in HepG2 cells (Figure 5f).
To gain a better insight on the consequences of TGF-
β-induced methylome switch on the phenotype, we per-
formed a whole genome expression analysis in both,
Huh7 and HepG2 cells. We chose the 8-days time point
(4 days of TGF-β treatment + 4 days post-release), consi-
dered in our model as the one defining long-term, stable
changes induced by this cytokine. Expression analysis
showed an expected profile of gene expression in both cell
lines, including known TGF-β targets (Additional file 7:
Table S4, Additional file 8: Figure S4c for qRT-PCR valida-
tions). In addition, “type I transforming growth factor beta
receptor binding” was the first gene ontology category at
the molecular function level (Additional file 7: Table S4).
However, when intersecting the expression (two-fold
change with an FDR < 0.05) and methylation (555 DMPs)
significant gene lists, there was no significant overlap. As
the effect of a specific methylation change on gene tran-
scription is known to depend on the genomic location
[24], we plotted all expression and methylation data,
and analyzed separately CpG island and non-CpG island
sites. As expected, no obvious correlation can be seen
when plotting simultaneously all genes, independently of
genomic location. However, hypermethylation within the
gene bodies positively correlated with gene expression
(Additional file 8: Figure S4a and S4b). In addition, we ob-
served a small but significant overlap of 30 genes when
intersecting the CD133 and the TGF-β methylation signa-
tures (p = 0.0013).
Our data shows that the effect of TGF-β in liver can-
cer cell lines comes along with a remarkable switch of
the DNA methylome at multiple loci. This reconfi-
guration is stable and common to two independent cell
lines, and affects a significant proportion of enhancer re-
gions and GC poor regions on gene bodies, which in
Figure 5 (See legend on next page.)
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Figure 5 Cell subpopulation imbalance induced by TGFβ correlates with a methylome reconfiguration. a. Huh7 and HepG2 cells were
treated with TGF-β for 4 days, or 4 + 4 days post-release, as described above. Biological triplicates were used to assess DNA methylation changes
with HM450 arrays. b. heatmap represents probes differentially methylated (FDR < 0.05) with a delta-beta of at least 20% (n = 41) between control
and TGF-β treated cells, in both cell lines, and both time points. For a full list of DMPs (FDR < 0.05 and delta-beta of at least 10%) see Table S3.
Blue indicates lower methylation, and red indicates higher methylation. The unsupervised clustering distinguishes TGF-β from control conditions
regardless of cell line or time of exposure. c. 555 DMPs (FDR < 0.05, delta > 10%) were mapped to known enhancer regions in the human hg19
genome assembly. Enrichment is observed in DMPs, relative to a random selection of the same number of probes and the total of HM450 probes
mapping to an enhancer (hg19). d. in similar way, GC content was compared between DMPs, random probes, and all HM450 probes (HM450).
(*) indicates a significantly lower GC content in DMPs relative to any of the other probe lists. e. DMPs were distributed according to their relationship
to CpG islands (CGI: islands, SHO: shores, SHE: shelves, or NC: non-CpG islands) or genes (DP: distal promoter, DS: distal sequence, GB: gene body,
IG: intergenic, and PP: proximal promoter), as described in Materials and Methods. f. A selection of significant loci were validated by pyrosequencing
(as described in Materials and Methods), in both cell lines. (*) indicates P value < 0.05 relative to non-treated cells at the corresponding time point and
cell line. IL-6 was included for comparison.
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The TGF-β “methyl-sensitive” signature described here
includes DNA methylation players themselves and a
number of TGF-β pathway loci, indicating a potential
role for DNA methylation in establishing a TGF-β-
induced phenotype switch in these cells. These results
suggest that basal CD133+ cells and TGF-β-induced
CD133+ cells only share a limited subset of their methy-
lome. An important fraction of TGF-β methyl-sensitive
CpG sites are not differentially methylated in CD133+
cells.Table 1 Differentially methylated regions (DMRs) after TGF-β
points (4 days treatment and 4 additional days post-release)
CHR Start End # probes E
chr1 2.26E + 08 2.26E + 08 3 2
chr10 1.35E + 08 1.35E + 08 6 1
chr12 1.21E + 08 1.21E + 08 4 8
chr13 92002338 92002454 2 4
chr15 78286548 78286614 2 9
chr16 87437787 87437924 2 8
chr17 48270042 48270097 3 1
chr17 48275324 48275919 2 1
chr17 73631586 73631785 2 6
chr17 80560479 80560634 3 3
chr19 23278023 23278036 2 1
chr19 24232204 24232430 2 9
chr20 31366437 31366486 3 1
chr5 52096641 52096811 2 5
chr6 33241410 33241770 4 6
chr7 1.35E + 08 1.35E + 08 3 8
chr7 1.57E + 08 1.57E + 08 3 1
chr9 1.33E + 08 1.33E + 08 2 2
See Methods for definition of DMR.Kinetics of DNA methylation changes at TGF-β
methyl-sensitive sites
Our methylome analyses have defined a subset of DNA
sites differentially methylated in response to TGF-β ex-
posure in a stable and cell line-independent fashion. We
performed two independent experiments to monitor the
dynamics of these DNA methylation changes induced by
TGF-β. First, we studied how early after TGF-β stimula-
tion we were able to observe methylation differences. To
this end, we extracted DNA every 24h during 4 consecu-
tive days in TGF-β treated and control cells grown inexposure in two liver cancer cell lines and two time
ntrezID Symbol Distance2TSS Promoter
052 EPHX1 0 TRUE
0844 TUBGCP2 2052 FALSE
4747 UNC119B 6288 FALSE
07975 MIR17HG 2264 FALSE
1450 LOC91450 0 TRUE
1631 MAP1LC3B 11986 FALSE
277 COL1A1 8903 FALSE
277 COL1A1 3081 FALSE
43008 SMIM5 2072 FALSE
607 FOXK2 6821 FALSE
E + 08 ZNF730 −21741 FALSE
534 ZNF254 15957 FALSE
789 DNMT3B 16246 FALSE
3918 PELO 12867 FALSE
222 RPS18 1558 FALSE
00 CALD1 111142 FALSE
0049 DNAJB6 1459 FALSE
3413 NCS1 34026 FALSE
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CpG site in the gene body of TRRAP, selected from our
list of significant hits as a representative of the pattern
most consistently observed in our dataset: differential
methylation of single sites (non-CpG island sites) in the
body of the genes. Basal methylation of TRRAP was rela-
tively stable within this experiment (Figure 6a). In con-
trast, TRRAP methylation is significantly increased as
early as 1 day in HepG2 cells and 2 days in Huh7 cells
after TGF-β exposure. This difference remains constant
up to the 4th day of TGF-β treatment in both cell lines.
In the second experiment we aimed to assess the sta-
bility of the methylation changes at longer time points.
To this end, cells were treated with TGF-β during 4 con-
secutive days (Figure 6b). After this time cell culture
medium was replaced by standard medium, and control
and treated cells were followed for DNA extraction every
4 days until day 16 (corresponding to day 12 post-release
from TGF-β exposure). First, we observed differences
on the basal methylation of TRRAP when comparing to
the previous experiments, especially in Huh7 cells
(Figure 6a). This could be the result of differences onFigure 6 Kinetics of DNA methylation after TGF-β treatment. a. Huh7
4 days), followed by DNA extraction, bisulfite modification, and pyrosequencin
hypermethylation in response to TGF-β, as seen in Figure 3b). b. in a similar w
4 days of TGF-β treatment. Cells were followed during 12 days post-release an
P value < 0.05 relative to non-treated cells at the corresponding time point anthe efficiency of bisulfite conversion between ex-
periments, but also differences between cell lines from
various origins, as the Huh7 cells used for the second
experiment were obtained from an independent labora-
tory. Regardless of basal difference, we observed that
the increased methylation of TRRAP was replicated in
both cell lines. Furthermore, significantly higher methy-
lation levels persisted up to 12 days post-release from
TGF-β, with no apparent change in its magnitude. Im-
portantly, cell growth was not significantly affected after
TGF-β release, and we estimate that at least 8 cell dupli-
cations took place during this time.
In summary, DNA methylation changes in a typical
TGF-β methyl-sensitive locus in the TRRAP gene body
can be observed as early as 1-2 days following TGF-β
exposure, and persist through cell division for at least 16
days without apparent change in magnitude.
Silencing of de novo DNA methyl-transferases impair the
effect of TGF-β at methyl-sensitive sites
To have an insight into the causal role of DNA methyla-
tion on the cancer cell population switch induced byand HepG2 cells were exposed to TGF-β for shorter time points (1 to
g analysis of one CpG site in the body of TRRAP gene (a DMP showing
ay, both cell lines were studied at longer time points after release from
d displayed a rate of proliferation close to non-treated cells. (*) indicates
d cell line.
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novo DNA methyl-transferases in the context of TGF-β ex-
posure in HepG2 cells using a pool of siRNAs (Methods).
The main readout of our experiment was the ability of
TGF-β to induce a 2- to 3-fold change in the expression
of CD133 by FACS analysis of HepG2 cells (as shown in
Figures 3a and 4a). Considering that the previous kinetics
experiment showed TRRAP hypermethylation at 2 days
post- TGF-β treatment, we started treatment with TGF-β
24h post-transfection and collected DNA two days later
(Figure 7a). siRNA efficiency checked by qRT-PCR
(Figure 7b) showed an effect of both siRNAs when used
alone or in combination, although siRNA against DNMT3B
displayed a better efficacy of silencing the corresponding
transcript. Transfection with a non-targeting siRNA did not
affect the morphology of HepG2 cells, typically growing as
refractive, well-delimited colonies (Figure 7c). The expected
response to TGF-β was also not affected by the non-
targeting siRNA, with the expected loss of the refractive
colonies and the presence of flattened enlarged cells. Trans-
fection with DNMT3A or DNMT3B siRNAs, or combi-
nation of both did not have any effect on cell morphology.
However, in contrast to the non-targeting control, there
was no response to TGF-β exposure and most cells re-
mained as refractive colonies in all other conditions without
significant loss of cell viability (Figure 7c). Similarly, non-
targeting siRNA did not influence the expected increase in
CD133+ expression by FACS (from 5.2% to 12.7% in aver-
age) (Figure 7d and 7e). There was no effect of siRNA
against DNMT3s alone or in combination on the basal ex-
pression of CD133. However, the response to TGF-β was
significantly impaired in all conditions (Figure 7d and 7e).
Therefore, the morphological “rescue” was paralleled by the
CD133 phenotype.
Finally, we tested if, under the same conditions, DNA
methylation changes in response to TGF-β were also im-
paired after DNMT3 silencing. TRRAP methylation is in-
duced after 2 days of TGF-β treatment in HepG2 cells, an
effect not influenced by the transfection of a non-targeting
siRNA (Figure 7f). However, all further experimental con-
ditions significantly reduce TRRAP methylation in the ab-
sence of TGF-β. In addition, the hypermethylation induced
by TGF-β exposure was impaired, especially after transfec-
tion with siRNA against DNMT3B. Together, these results
suggest that de novo DNA methyl-transferases are involved
in the effect of TGF-β at different levels: morphology, dis-
tribution of cell subpopulations, and DNA methylation.
The hypomethylation observed in absence of TGF-β also
suggests a role for DNMT3A and DNMT3B in main-
tenance of DNA methylation at the TRRAP locus.
Discussion and conclusions
In the present report, we comprehensively describe the
DNA methylome of CD133+ and CD133- liver cancercells. We used two non-related HCC cell lines to isolate
pure populations of CD133- and CD133+ cells for
DNA methylome assays. As has been previously reported,
CD133+ cells isolated from liver cancer cell lines (inclu-
ding those used in the present study), are functionally
distinct cells with increased ability to induce tumors in
animal models [14]. These findings are in line with clinical
studies reporting poor prognosis for those HCC cases dis-
playing higher proportions of CD133-expressing cells. Al-
though testing the tumor-initiating or metastasis-initiating
ability of CD133+ cells was beyond the scope of our study,
our results suggest that these cells display a differential
DNA methylation signature. Whether DNA methylation
is fundamental in establishing the cellular programs de-
fining the main characteristics of these cells should be the
focus of future studies.
Recently, the prognostic implications of TGF-β pathway
activation in HCC have been linked to the ability of this
signaling pathway to induce metastatic behavior in a frac-
tion of HCC cells [25]. An additional link between liver
TICs and TGF-β in HCC has been the recent demon-
stration that TGF-β is able to increase the proportion of
CD133+ cells in vitro [17]. Here, we were able to repro-
duce and extend those previous observations. We showed
that TGF-β is able to increase CD133 expression at the
protein and mRNA level in two non-related HCC cell
lines. The effect induced by TGF-β is stable, as opposed to
the transient effect of the proinflammatory cytokine IL-6.
We show that this effect depends on specific signaling
through TGF-β type I receptor and is independent of
increased cell proliferation of CD133+ cells. By using
CD133-depleted cellular fractions, we suggest that TGF-β
is able to induce de novo expression of CD133. Fur-
thermore, this induction of CD133 cells correlates with an
increased ability to grow in non-attachment conditions, a
surrogate functional assay for stem/TIC properties.
Both, basal CD133-expressing cells and TGF-β-induced
CD133+ cells, expressed increased levels of the de novo
DNA methylation transcripts, DNMT3A and DNMT3B.
This led us to further explore the ability of TGF-β to in-
duce DNA methylation changes at the genome-wide level.
We were able to show cell line-independent changes in
DNA methylation induced by TGF-β in a stable fashion,
suggesting an epigenetic mechanism involved in the
establishment of a cellular program. The methylome of
TGF-β -treated cells only partially overlapped with the
methylome of CD133+ cells in basal conditions. This sug-
gests that TGF-β may not only induce CD133 expression
(or an increase in the CD133-expressing subpopulation),
but also a defined DNA methylation profile. Further stu-
dies at longer time points and analyses of isolated CD133
negative and positive cells may shed light on the ability of
TGF-β to imprint a DNA methylation signature indepen-
dently of the induction of CD133 expression.
Figure 7 Silencing of DNMT3s impairs the effects of TGF-β on liver cancer cells. a. HepG2 cells were transfected with 20nM of a non-targeting
siRNA, or a pool of siRNAs against DNMT3A, DNMT3B, or a combination of both. One day after transfection cell medium was replaced by standard
culture medium or medium containing 10nM TGF-β for each condition. Two days after treatment with TGF-β cells were collected from all conditions for
morphological evaluation, CD133 FACS expression analysis, RNA and DNA extraction. All transfections were performed in triplicate wells. b. qRT-PCR
was performed to assess the efficiency and specificity of the transfections. Higher efficiency was obtained with siRNA against DNMT3B alone or in
combination with DNMT3A. c. Representative Phase contrast images for all conditions (compare with Figure S2c for the morphology of non-transfected
HepG2 cells in basal conditions and in response to TGF-β). d. cells were collected after treatment and processed immediately for analysis of CD133
surface expression using FACS. Secondary antibody staining (with no primary CD133 staining) is shown as control in the top panel, and was used as a
reference for the gates shown below. The plots show one representative histogram for each condition, and the corresponding percentage of CD133+
cells (compare with Figure 1a and Figure 7e for the basal expression and variation in HepG2 non-transfected cells). e. Mean + SEM for CD133 FACS
expression in triplicates of each condition. A non-transfected control was also included in this analysis. Asterisks depict the significance between control
and TGF-β -treated cells transfected with non-targeting siRNA, and all other TGF-β -treated conditions compared to non-targeting TGF-β -treated cells.
f. DNA was extracted and bisulfite modified for pyrosequencing of TRRAP. (*) indicates P value < 0.05 relative to non-treated cells within each
experimental condition.
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http://www.biomedcentral.com/1471-2164/15/435Notably, although TGF-β is known to induce DNA
methylation changes at discrete loci [26-28], little evidence
existed to date of a genome-wide level of TGF-β-methyl-
sensitive loci. Specifically, several previous reports were
focused on chromatin changes associated with epithelial-
mesenchymal transition (EMT). EMT is a developmental
process that involves actin cytoskeleton reorganization
and loss of apical–basal polarity and cell-to-cell contact,
and like other developmental processes it involves epige-
netic reprogramming [29]. However, both at physiological
and pathological levels, EMT has been mainly linked to
widespread changes of histone marks or histone modifiers,
in addition to the well-known role of defined transcription
factors [30-32]. Interestingly, gene-specific changes in
DNA methylation have been correlated with the ability to
maintain epigenetic silencing of critical EMT genes [27].
In this sense, it has been suggested that DNA methylation
is involved in the process of fixing the switch between epi-
thelial and mesenchymal phenotypes. In our conditions,
TGF-β induced a loss of E-Cadherin expression in both
cell lines, but not an evident increase in N-Cadherin,
which is a known marker of EMT (Additional file 4:
Figure S2f). However, our results are consistent with a
model of persistent changes in DNA methylation induced
by TGF-β. Indeed, our experimental design was intended
to reproduce an epigenetic process, by selecting only those
changes in DNA methylation that survived cell division.
Whether this effect of TGF-β is specific of transformed
cells will require further studies.
Regardless of considerations on the targeted cells or the
effect of the cell cycle or cell subtypes, we describe what
seems to be a unique pattern of differential methylation.
Our TGF-β signature (stable after TGF-β removal, and
common to two liver cancer cell lines) was characterized
by a reduced GC content, and enrichment at enhancer re-
gions. Moreover, the under-representation of promoter
CGIs and enrichment on gene bodies (together with the
positive correlation with gene expression in a subset of
these sites), may indicate specific mechanisms of gene
regulation through DNA methylation. For example, chan-
ges in DNA methylation on these TGF-β methyl-sensitive
loci may drive differential enhancer activity or alternative
transcriptional events, as has been suggested in other con-
texts [23]. Whether similar findings occur in response to
other cytokines is not currently known.
In summary, our data support and reinforce several pre-
vious studies that have pointed to an association between
TICs, and TGF-β. In addition, we provide a mechanistic
insight into the process that may lead to the stable change
in cancer cell subpopulations. Our study demonstrates
that a key cytokine involved in HCC progression, TGF-β,
is able to epigenetically induce a dynamic imbalance bet-
ween cell subpopulations. The results reported here are in
agreement with a model in which DNA methylation playsa pivotal role in establishing the cellular program of liver
cancer cell subpopulations. The dynamics of a related
process has recently been shown for CD44+ breast cancer
stem cells [33]. However, in our model, the effect of
TGF-β is persistent (as compared to the effect of another
cytokine, IL-6) and therefore epigenetically acquired. Mo-
tivated by these observations, the mechanistic evidence of
an active interplay between TGF-β and the DNA methyla-
tion machinery should be an exciting focus of future
studies.
Methods
Cell culture and treatments
Huh7 and HepG2 cells (American Type Culture Condi-
tions) were cultured in DMEM medium (Gibco) at 37°C
and 5% CO2, and were regularly tested for mycoplasma
contamination (MycoAlert detection kit, Lonza).
For cytokine treatments, cells were plated and allowed
to adhere before adding medium containing 10ng/ml final
of IL-6 or TGF-β1 (recombinant human, Peprotech). For
inhibition experiments, cells were treated with 2 μM
SB-431542 (Sigma-Aldrich) alone or in combination with
TGF-β1.
For spheres formation assay, hepatosphere medium
was prepared as previously reported [34]. Spheres were
counted after 5 or 6 days.
siRNA non-targeting and pool siRNAs against DNMT3A
and DNMT3B (Dharmacon, On-Target plus siRNA) were
transfected at 20nM using RNAiMAX lipofectamine (Life
Technologies) as recommended by the manufacturer. Cells
were washed and medium was replaced 12 hours after
transfection.
Fluorescence Activated Cell Sorting (FACS)
Cells were labeled with antibodies against CD44, CD133
(AC133), EpCAM, CD90 or TGFBRII (Additional file 9:
Table S5). Secondary antibodies were conjugated alterna-
tively with FITC, Cy3 or Alexa750.
To study cell cycle progression, bromodeuxyridine
(BrdU) (Sigma) incorporation and DNA content were
simultaneously assessed, as previously described [35].
Fluorescent events were captured using FACS instru-
ment (FACSCanto II, BD Biosciences), and analyzed
using BD FACSdiva 6.0 (BD Biosciences software) and
WinMDI software (version 2.9).
Magnetic Activated cell sorting (MACS)
Huh7 and HepG2 cells were depleted or enriched for
CD133+ cells using magnetic-activated cell sorting (MACS,
Miltenyi Biotec), with some adaptations to the manufac-
turer’s instructions. Cells were incubated 30 min at 4°C
with FcR blocking reagent, followed by 15 min incubation
with MicroBeads conjugated to monoclonal anti human
CD133 antibodies. After washing, cell suspension was
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netic field of a MACS separator. For CD133+ depletion,
flow-through the LS column containing unlabelled cells
was collected. For CD133+ enrichment, the column was
removed from the separator and placed on a 15 ml collec-
tion tube. Labeled cells were collected by firmly pushing
the plunger in the column. To increase purity of CD133+
cells, the eluted fraction was enriched a second time over a
new LS column. For each experiment, aliquots were kept
to test by FACS the efficiency of the enrichment.
Bisulfite modification and pyrosequencing
To quantify the percentage of methylated cytosine in in-
dividual CpG sites, we performed bisulfite pyrosequenc-
ing, as previously described [36]. For samples processed
for Infinium bead arrays, the conversion was performed
on 600 ng of DNA using the EZ DNA methylation Kit
(Zymo Research) and modified DNA was eluted in 16 ul
of water. Quality of modification was checked by PCR
using modified and unmodified primers for GAPDH
gene. Pyrosequencing assays (primers for PCR, sequen-
cing primers and regions) are described in Additional
file 9: Table S6.
Bead array methylation assays
Methylation profiles of the different samples were
analyzed using the HM450 Infinium methylation bead
arrays (Illumina, San Diego, USA). Briefly the HM450
beadchip interrogates more than 480,000 methylation
sites [19]. The analysis on the bead array was conducted
following the recommended protocols for amplification,
labeling, hybridization and scanning. Each methylation
analysis was performed in duplicate (for CD133+ versus
CD133- samples) or in triplicate (for all other methy-
lome analyses).
Whole genome expression array
Total RNA was isolated using the TRIzol Reagent
(Invitrogen) according to the manufacturer’s instructions.
RNA quantity and quality were assessed with a ND-8000
spectrophotometer and bioanalyzer. 500 ng of total RNA
was used for each Human HT-12 Expression BeadChips
(Illumina), as previously described [37]. 10 candidate genes
were selected for validation using quantitative RT-PCR.
Four different housekeeping genes (HPRT1, GAPDH,
SFRS4 and TBP1) were alternatively used for internal
control. The different primers used are listed in Additional
file 9: Table S7.
Immunoblotting and immunofluorescence
Protein extraction and immunoblotting was performed
as previously described [37]. Immunostaining was per-
formed with anti-SMAD3, anti-phosphorylated SMAD3
and anti-tubulin/actin for loading control.For immunofluorescence Huh7, HepG2, and 3T3
cells grown in cover slips were fixed in 4% formaldehyde
for 20 min and then washed and stained with primary
antibodies against E-Cadherin and N-Cadherin (Novus
Biological). Alexa Fluor 488 and Alexa 555 (Life Biotech-
nologies) were used as secondary antibodies, and TO-
PRO-3-iodide (Life Biotechnologies) for counterstaining.
An Axiovert LSM 510 confocal microscope (Zeiss, Jena,
Germany) was used for image collection. Images were
analyzed using LSM image browser software (Zeiss).
Bioinformatics analysis
Raw expression bead array data was exported from Genome
Studio (version 2010.3, Illumina) into BRB-ArrayTools soft-
ware (version 4.3.1, developed by Dr. Richard Simon and
the BRB-ArrayTools Development Team), as previously
described [37]. Data was normalized and annotated using
the R/Bioconductor package “lumi” [38]. Class com-
parison between groups of bead arrays was done compu-
ting a t-test separately for each gene using the normalized
log-transformed beta values. Only those probes with
FDR < 0.05 and a fold-change of two were considered dif-
ferentially expressed. WebGestalt (WEB-based GEne SeT
AnaLysis Toolkit) web application was used for gene set
enrichment analyses, including Gene Ontology, and path-
ways [39].
For methylome analyses we used a combination of
R/Bioconductor packages (following recent guidelines for
HM450 data mining) [40,41]. “WateRmelon” package was
used to load the raw data directly from idat files into a
MethyLumiSet object [38,42]. Data quality was inspected
using boxplots for the distribution of methylated and
unmethylated signals, and inter-sample relationship using
multidimensional scaling plots and unsupervised clus-
tering. Probes were filtered for low bead count, low quality
(detection P value > 0.05), and recently described cross-
reactive probes [43]. Then, we performed color bias ad-
justment, followed by inter-sample quantile normalization,
and probe bias correction with intra-array beta-mixture
quantile normalization, as described [44]. Methylation
beta values were logarithmically transformed to M values,
better suited for parametric statistical analyses [45]. M
values were used to determine batch effects using princi-
pal component analysis, and corrected with the surrogate
variable analysis package (“sva”) [46]. To obtain a com-
mon differential methylation between control and TGF-β-
treated cells we used the “limma” package with TGF-β
exposure as the main variable, using the cell line (Huh7
and HepG2) as a co-factor in the linear model [47]. Dif-
ferentially methylated positions (DMPs) were defined as
those sites with a methylation difference (delta-beta) of
10% in any direction with an FDR-adjusted p value below
0.05. To study the genomic context of DMPs we used
HM450 annotations, with hg19 as the human reference
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cent publication using HM450 bead arrays [23]. Finally,
we used the “methyAnalysis” package to identify differen-
tially methylated regions (DMRs) after transforming our
dataset to a list of genomic regions followed by methyla-
tion data smoothing, as described (Pan Du and Richard
Bourgon [2013]. methyAnalysis: DNA methylation data
analysis and visualization. R package version 1.2.0). We
defined DMR as a region with at least two differentially
methylated probes, and a minimum gap of 100 bp.
To study differential methylation between CD133 nega-
tive and positive cells we performed a class comparison
blocking by cell line status (Huh7 or HepG2). The analysis
performed is an analysis of variance for a randomized
block design. Two linear models are fit to the methylation
data for each gene. The full model includes class variable
and the block variable, and the reduced model includes
only the block variable. Likelihood ratio test statistics are
used to investigate the significance of the difference
between the classes. In this comparison we set a p value
threshold <0.001 and 5% difference in methylation. For all
other comparisons, only those probes with FDR-corrected
p values <0.05 were considered significant.
Statistical analysis
BRBArrayTools and R/Bioconductor packages were used
for bead array analyses, as described above. For other
comparisons, means and differences of the means with
95% confidence intervals were obtained using GraphPad
Prism (GraphPad Software Inc.). Two-tailed student t test
was used for unpaired analysis comparing average expres-
sion between classes. P values < 0.05 were considered sta-
tistically significant.
Additional files
Additional file 1: Figure S1. A. Percentage of positive cells for candidate
liver cancer stem cell markers, in two unrelated liver cancer cell lines, Huh7
and HepG2. B. cell lines were sorted using MACS (as described in Materials
and Methods) and RNA was extracted to study the expression of stemness
transcription factors (NANOG, POU5F1/Oct4, and SOX2) by qRT-PCR.
Intermediate levels of CD133 enrichment were also included, so that
increasing expression of CD133 is shown from left to right within each
panel. A representative experiment of at least three independent MACS
assays per cell line is shown. C. sphere formation assay comparing CD133-
and CD133+ cells in Huh7 cells. After MACS purification, cells were plated in
non-attachment plates, and their growth as spheres was quantified after 6
days. Only structures grown in suspension, with refractory well-defined
limits, were counted as spheres. Mean and SD from 3 technical replicates is
shown on the left panel. One representative image of each condition is
shown on the right panel.
Additional file 2: Table S1. Differentially methylated sites in CD133- vs.
CD133+ cells, based on Infinium HM450 data.
Additional file 3: Table S2. Gene set enrichment analyses using
BRBArray Tools, and comparing the methylomes of CD133- and CD133+
cells in two cell lines, Huh7 and HepG2.
Additional file 4: Figure S2. A. FACS analysis of TGFBRII expression in
Huh7 and HepG2 cells in basal conditions. Percentage of positive cellsrelative to background secondary antibody is shown in each chart.
B. western blot for SMAD proteins was performed for the two cell lines,
in control conditions, or after stimulation with TGF-β during 4 days.
C. representative phase contrast images of Huh7 and HepG2 cells left
untreated or exposed to IL-6 or TGF-β during 4 days. D. viability was
assessed by trypan blue exclusion in cells treated or not with IL-6 or
TGF-β during the indicated time points. Percentages of trypan positive
cells are represented on the bar plots. E. Representative phase contrast
images of Huh7 and HepG2 cells treated from 1-3 days with the
indicated conditions: mock, DMSO, TGF-β receptor I inhibitor (SB-431542),
TGF-β alone or in combination with SB-431542 inhibitor. All conditions
were performed in triplicate culture wells. F. Control and TGF-β -treated
cells were fixed and stained for expression of E-Cadherin (FITC) and
N-Cadherin (Cy3). E-Cadherin is lost upon treatment in both cell lines
and time points (4 and 8 days). N-Cadherin staining was low to absent in
all conditions, despite a clear signal in control 3T3 cells (right panel).
Additional file 5: Figure S3. A. BrdU uptake was used to estimate the
proliferation index of both cell lines in different culture conditions, and
after two time points. FACS analysis was performed in combination
with propidium iodide staining to separate the cells by cell cycle stage.
B. mRNA expression of CD133 in the same conditions described for
Figure 4a. C. Non-attachment growth assay was performed after 4 days
post-release from a 4 day treatment with TGF-β. Sphere formation was
assessed 6 days after culture with hepatosphere medium. (*) indicates
P value < 0.05 relative to non-treated.
Additional file 6: Table S3. List of differentially methylated sites in
response to TGF-β and in two cell lines, Huh7 and HepG2 (TGF-β
signature).
Additional file 7: Table S4. Genes differentially expressed (including
gene ontology and pathway analysis) in response to TGF-β.
Additional file 8: Figure S4. A. Correlation between methylation and
expression at the genomic regional level in Huh7 cells. Panels show the
correlation of delta_Beta (methylation) in the x axis and fold-change
(expression) in the y axis. Upper panels correspond to all RefSeq genes
without any filter, or separately for CpG-island (CGI) or non-CGI related
sites. Lower panels show the same analysis after filtering for differentially
methylated and differentially expressed genes. Examples of specific
genomic regions (i.e. TSS200, TSS1500, or Gene Body) are listed below
the lower panels. The same analysis in HepG2 cells is shown in (B). C. A
selection of significant genes was validated by qRT-PCR in both cell lines.
(*) indicates P value < 0.05 relative to non-treated.
Additional file 9: Table S5. List of antibodies used for characterization
of liver cancer stem cells.Table S6. List of pyrosequencing assays.
Table S7. List of primers used for qRT-PCR.
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